Stock Price
350.00
Daily Change
-10.50 -2.91%
Monthly
20.90%
Yearly
-60.30%
Q3 Forecast
344.93

Peers Price Chg Day Year Date
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Novo Nordisk A/S 350.00 -10.50 -2.91% -60.30% Sep/05
Novo Nordisk 55.22 -0.93 -1.66% -57.89% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05
Bausch Health Companies 10.18 0.20 2.00% 20.90% Sep/05

Indexes Price Day Year Date
EU600 549 -0.88 -0.16% 8.42% Sep/05

Novo Nordisk A/S traded at 350.00 this Friday September 5th, decreasing 10.50 or 2.91 percent since the previous trading session. Looking back, over the last four weeks, Novo Nordisk A/S lost 20.90 percent. Over the last 12 months, its price fell by 60.30 percent. Looking ahead, we forecast Novo Nordisk A/S to be priced at 344.93 by the end of this quarter and at 330.14 in one year, according to Trading Economics global macro models projections and analysts expectations.